Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.30 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SDHB | P21912 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054887 | 1.00 | BRD4 (0.35) | BRD4NPC1P2RX7LMNAKDM4E | |
| SCHEMBL3854400 | 0.86 | BRD4 (0.38) | BRD4NPC1BRD2BRD3BRDT | |
| SCHEMBL3452348 | 0.85 | BRD4 (0.39) | BRD4NPC1LMNAKDM4EBRD2 | |
| SCHEMBL3452342 | 0.85 | BRD4 (0.39) | BRD4NPC1LMNAKDM4EBRD2 | |
| SCHEMBL3452346 | 0.85 | BRD4 (0.39) | BRD4NPC1LMNAKDM4EBRD2 | |
| SCHEMBL11886698 | 0.81 | SYK (0.38) | BRD4NPC1P2RX7L3MBTL1KMT2A | |
| SCHEMBL5506152 | 0.78 | BRD4 (0.46) | BRD4NPC1KDM4EBRD2BRD3 | |
| SCHEMBL1929365 | 0.78 | BRD4 (0.46) | BRD4NPC1KDM4EBRD2BRD3 | |
| SCHEMBL3848615 | 0.78 | TLR8 (0.39) | BRD4SDHB | |
| SCHEMBL3856066 | 0.78 | MAPT (0.40) | BRD4P2RX7LMNAMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003791-A1 | Cyclized Derivatives as EG-5 Inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003791-A1 | Cyclized Derivatives as EG-5 Inhibitors | CYP3A5, GDI2, HDAC5 | BRD4 2965/4885NPC1 191/4885P2RX7 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.